0.29
0.29 (0%)
As of Feb 14, 2025
Cellectar Biosciences, Inc. [CLRB]
Source:
Company Overview
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid ether drug conjugate ™ (PDC™) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects.
| Country | United States |
| Headquarters | florham park, new jersey |
| Phone Number | (608) 441-8120 |
| Industry | manufacturing |
| CEO | James V. Caruso |
| Website | www.cellectar.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-51.8 |
| Net Income | $-44.6 |
| Net Cash | $13.7 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -237.5% |
| Profit as % of Stockholder Equity | -311.9% |
Management Effectiveness
| Return on Equity | -311.9% |
| Return on Assets | -175% |
| Turnover Ratio | |
| EBITA | $-51.8 |
Balance Sheet and Cash Flow Measures
| Total Assets | $25.5 |
| Total Liabilities | $9.8 |
| Operating Cash Flow | $-47.6 |
| Investing Cash Flow | $-0.1 |
| Financing Cash Flow | $61.4 |
